Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences Inc.

Moderna ( ($MRNA) ) has risen by 22.69%. Read on to learn why. Moderna’s shares have surged 22.69% over the past week, as investors warmed to the c...

Moderna Stock Jumps as Pipeline Hype Outruns Wall Street

An update from TransCode Therapeutics ( ($RNAZ) ) is now available. On June 18, 2026, TransCode Therapeutics posted an investor presentation outlin...

TransCode Highlights Progress of Lead RNA Cancer Therapeutic

The latest update is out from Cartesian Therapeutics ( ($RNAC) ). On June 12, 2026, Cartesian Therapeutics, Inc. held its 2026 Annual Meeting of St...

Cartesian Therapeutics Shareholders Back Directors and Governance Measures

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Moderna, with a price target of $41.00. Meacham covers the Healthca...

Citi Sticks to Its Hold Rating for Moderna (MRNA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNA) and Scienture Holdings (SCNX). Moderna (MRNA) Will...

Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Madrigal Pharmaceuticals (MDGL), Moderna (MRNA) an...

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Moderna (MRNA) and Ionis Pharmaceuticals (IONS)

Wedbush analyst maintained a Buy rating on Cartesian Therapeutics yesterday and set a price target of $38.00. The company’s shares closed yesterday...

Wedbush Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

Moderna ($MRNA) announced an update on their ongoing clinical study. ModernaTX, Inc. (MRNA) is running a Phase 2 trial called “A Study of mRNA-1345...

Moderna’s Maternal RSV Vaccine Study Reaches Completion: What Investors Should Watch

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna yesterday. The company’s shares closed yesterday at $47.73. Breen covers the H...

Moderna (MRNA) Gets a Hold from Bernstein

An update from Cartesian Therapeutics ( ($RNAC) ) is now available. On June 9, 2026, Cartesian Therapeutics announced a strategic licensing agreeme...

Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNA) and Glaukos (GKOS). Moderna (MRNA) William Blair a...

Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Glaukos (GKOS)

Moderna ($MRNA) announced an update on their ongoing clinical study. Moderna (MRNA) has updated a key early‑stage study of its cytomegalovirus, or ...

Moderna’s CMV Vaccine Study Update: What mRNA‑1647 Progress Means for MRNA Investors

Barclays analyst Eliana Merle maintained a Hold rating on Moderna today and set a price target of $48.00. According to TipRanks, Merle is a 3-star ...

Barclays Sticks to Their Hold Rating for Moderna (MRNA)

Alterity Therapeutics ( ($AU:ATH) ) just unveiled an update. Alterity Therapeutics has changed its registered office address to Level 15, 500 Colli...

Alterity Therapeutics Updates Registered Office Address in Melbourne

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNA) and Mediwound (MDWD). Moderna (MRNA) In a report r...

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Mediwound (MDWD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Labcorp Holdings (LH), Moderna (MRNA) and Celcuity...

Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH), Moderna (MRNA) and Celcuity (CELC)

The latest announcement is out from TransCode Therapeutics ( ($RNAZ) ). TransCode Therapeutics said it plans to hold its 2026 annual meeting of sto...

TransCode Sets Key Deadlines for 2026 Shareholder Meeting

Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Moderna yesterday and set a price target of $32.00. According to TipR...

Moderna (MRNA) Gets a Sell from Bank of America Securities

Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics said shareholders passed resolutions at its 2026 Extraordinary Gene...

Alterity Investors Approve Resolutions, Clearing Path Toward Pivotal MSA Trial

Moderna ($MRNA) announced an update on their ongoing clinical study. The Phase 2 study “A Phase 2, Randomized, Observer-blind, Dose-finding, Placeb...

Moderna Advances mRNA Lyme Disease Vaccine Into Phase 2: What Investors Should Watch

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tarsus Pharmaceuticals (TARS) and Cartesian Therapeu...

Wall Street Analysts Are Bullish on Top Healthcare Picks

H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Cartesian Therapeutics today and set a price target of $25.00. According to TipR...

H.C. Wainwright Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on LifeMD (LFMD), Corbus Pharmaceuticals (CRBP) and Car...

Analysts Are Bullish on These Healthcare Stocks: LifeMD (LFMD), Corbus Pharmaceuticals (CRBP)

Insiders have been trading these 5 stocks: (($JPM)), (($CVX)), (($MSTR)), (($MRNA)) and (($SNAP)). Here is a breakdown of their recent trades and t...

JPMorgan, Chevron, Strategy, Moderna, Snap Insider Shake-Up

An update from TransCode Therapeutics ( ($RNAZ) ) is now available. On May 19, 2026, TransCode Therapeutics disclosed that it received a deficiency...

TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice

In a report released today, Alec Stranahan from Bank of America Securities maintained a Sell rating on Moderna, with a price target of $32.00. Acco...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RNA	$12.66	+1.44%	294.10K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RNA	$12.66	+1.4%	294.10K
3
4
5
6

RNA

RNA

Get Avidity Biosciences Inc. Data in Excel

Get Avidity Biosciences Inc. Data in Excel